Advertisement

Topics

FDA signs off on late-stage trial for Erytech's pancreatic cancer drug

06:00 EDT 14 May 2019 | SmartBrief

An investigational new drug application for Erytech Pharma's second-line pancreatic cancer drug candidate eryaspase has gaine -More

Original Article: FDA signs off on late-stage trial for Erytech's pancreatic cancer drug

NEXT ARTICLE

More From BioPortfolio on "FDA signs off on late-stage trial for Erytech's pancreatic cancer drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Pancreatitis
Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake.  Diagnosis is based on clinical presentation...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...